← The Library Research Portal →

Blood Biomarkers of Aging: A Comprehensive Scientific Guide

Blood biomarkers represent the most accessible and actionable window into the aging process. While epigenetic clocks measure methylation patterns and composite biological age algorithms integrate multiple data streams, routine blood tests offer immediate insights into systemic aging at a fraction of the cost. This comprehensive guide examines the current scientific understanding of blood-based aging biomarkers, from well-established inflammatory and metabolic markers to emerging predictive algorithms powered by deep learning.

Why Blood Biomarkers Matter for Aging Assessment

Blood is a dynamic tissue that interfaces with every organ system, making it an ideal medium for detecting systemic aging processes. Unlike tissue biopsies or advanced imaging, blood tests are minimally invasive, widely available, and standardized across clinical laboratories. This accessibility enables longitudinal tracking—the cornerstone of personalized aging intervention.

The hallmarks of aging framework identifies nine interconnected processes that drive biological decline: genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, deregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, and altered intercellular communication. Blood biomarkers capture signals from many of these hallmarks, particularly inflammation, metabolic dysregulation, and mitochondrial stress.

More importantly, blood biomarkers are modifiable. Unlike genetic risk scores or chronological age, most blood-based aging markers respond to interventions such as caloric restriction, exercise, targeted geroprotectors, and sleep optimization. This actionability transforms biomarker tracking from passive observation to active optimization.

Inflammatory Markers: The Fire That Ages Us

Chronic low-grade inflammation—termed "inflammaging"—is one of the most robust predictors of morbidity and mortality in aging populations. The immune system shifts from acute, pathogen-clearing responses to persistent, sterile inflammation driven by cellular senescence, mitochondrial dysfunction, and gut barrier disruption. This section examines the key inflammatory biomarkers accessible through routine blood panels.

C-Reactive Protein (CRP) and High-Sensitivity CRP (hsCRP)

CRP is an acute-phase protein produced by the liver in response to inflammatory cytokines, particularly interleukin-6 (IL-6). Standard CRP assays measure levels above 3 mg/L, useful for detecting active inflammation. High-sensitivity CRP (hsCRP) extends the measurement range down to 0.1 mg/L, capturing the subtle chronic inflammation characteristic of aging and cardiovascular disease.

Epidemiological studies consistently link elevated hsCRP to increased risk of cardiovascular events, type 2 diabetes, cancer, and all-cause mortality. The Framingham Heart Study found that individuals with hsCRP levels above 3 mg/L had double the risk of cardiovascular events compared to those below 1 mg/L. Longevity-optimized targets aim for hsCRP below 1 mg/L, with levels below 0.5 mg/L considered ideal.

CRP is highly responsive to lifestyle interventions. Regular aerobic exercise reduces hsCRP by 20-40% in meta-analyses, while caloric restriction and Mediterranean dietary patterns show similar reductions. Metformin, the most studied geroprotector, lowers CRP through AMPK activation and reduced hepatic cytokine production.

Interleukin-6 (IL-6)

IL-6 is a pleiotropic cytokine with both pro-inflammatory and anti-inflammatory functions depending on context. Circulating IL-6 increases 2-4 fold between ages 20 and 80, driven by senescent cell secretion, adipose tissue expansion, and chronic immune activation. Elevated IL-6 predicts frailty, muscle wasting (sarcopenia), and mortality independent of other inflammatory markers.

The Baltimore Longitudinal Study of Aging found that individuals in the highest IL-6 tertile had 50% higher mortality risk over 5 years compared to the lowest tertile. IL-6 also drives hepatic CRP production, creating a feed-forward inflammatory loop. Optimal IL-6 levels remain below 2 pg/mL, though most commercial labs report reference ranges extending to 10 pg/mL.

IL-6 is less modifiable than CRP through lifestyle alone, though NF-κB pathway inhibition via compounds like curcumin and omega-3 fatty acids shows promise. Senolytics that clear senescent cells—a major IL-6 source—are under investigation for reducing systemic IL-6 burden.

Tumor Necrosis Factor Alpha (TNF-α)

TNF-α is a key mediator of systemic inflammation, produced primarily by macrophages and adipocytes. Like IL-6, TNF-α levels increase with age and correlate with insulin resistance, muscle wasting, and cardiovascular disease. TNF-α also activates NF-κB signaling, perpetuating inflammatory cascades.

Elevated TNF-α interferes with insulin signaling by promoting serine phosphorylation of insulin receptor substrate-1 (IRS-1), linking inflammation directly to metabolic dysfunction. Anti-TNF-α therapies used in rheumatoid arthritis improve insulin sensitivity, though systemic immunosuppression limits their use as anti-aging interventions.

Growth Differentiation Factor 15 (GDF-15): The Emerging Star

GDF-15 has emerged as one of the most promising aging biomarkers over the past five years. Originally identified as a stress-response cytokine, GDF-15 is now recognized as a mitokine—a signaling molecule released in response to mitochondrial dysfunction and cellular stress. Circulating GDF-15 increases exponentially with age, doubling every 10-15 years after age 50.

Recent 2025 research published in Scientific Reports demonstrated that skeletal muscle mitochondrial dysfunction is directly associated with increased GDF-15 expression and circulating levels in aged mice. A 2025 preprint on bioRxiv examined blood mitochondrial health markers, finding that circulating cell-free mitochondrial DNA (cf-mtDNA) and GDF-15 are strongly correlated in human aging.

GDF-15 predicts all-cause mortality, cardiovascular events, and cancer incidence across multiple cohorts. The UK Biobank analysis found that each standard deviation increase in GDF-15 was associated with 38% higher mortality risk over 7 years. Unlike CRP, which fluctuates with acute infections, GDF-15 remains relatively stable, making it a robust longitudinal biomarker.

GDF-15 also correlates with functional decline. 2025 research in Molecular Genetics and Metabolism showed that GDF-15 in saliva correlated with neurological symptoms, fatigue, and functional capacity in mitochondrial disease patients. The biomarker is now recognized as quantifiable across multiple biological fluids and responsive to stress-evoked changes.

Optimal GDF-15 levels remain below 400 pg/mL in middle-aged adults, though reference ranges vary by assay. Interventions targeting mitochondrial function—such as NAD+ precursors, exercise training, and mitochondrial-targeted antioxidants—show promise for reducing GDF-15, though long-term clinical trial data remain limited.

Metabolic Markers: Glucose, Insulin, and Energy Homeostasis

Metabolic dysregulation is a central feature of aging, driven by insulin resistance, mitochondrial decline, and disrupted nutrient sensing. The following markers capture different aspects of glucose metabolism and provide actionable targets for intervention.

Fasting Glucose

Fasting plasma glucose (FPG) measures blood sugar after an overnight fast, reflecting hepatic glucose output and baseline insulin action. Standard reference ranges classify FPG below 100 mg/dL as normal, 100-125 mg/dL as prediabetic, and above 126 mg/dL as diabetic. However, longevity-optimized targets aim for FPG between 70-85 mg/dL.

Even within the "normal" range, higher FPG predicts future diabetes risk and cardiovascular events. The Whitehall II study found that individuals with FPG of 95-99 mg/dL had 2.3 times the risk of developing diabetes compared to those below 85 mg/dL. FPG also correlates with IGF-1/insulin signaling, a key longevity pathway modulated by caloric restriction and fasting.

Hemoglobin A1c (HbA1c)

HbA1c measures the percentage of hemoglobin glycated by glucose over the preceding 2-3 months, providing a time-averaged picture of glycemic control. Unlike fasting glucose, which captures a single time point, HbA1c integrates postprandial glucose excursions and chronic hyperglycemia.

Standard thresholds classify HbA1c below 5.7% as normal, 5.7-6.4% as prediabetic, and above 6.5% as diabetic. Longevity optimization targets HbA1c below 5.4%, with some advocates aiming for 5.0% or lower. Each 0.5% increase in HbA1c above 5.0% is associated with 20-30% higher cardiovascular risk in meta-analyses.

HbA1c responds well to dietary interventions, particularly low-glycemic-index diets, time-restricted eating, and carbohydrate reduction. Metformin lowers HbA1c by 0.5-1.0% through improved insulin sensitivity and reduced hepatic gluconeogenesis.

Fasting Insulin and HOMA-IR

Fasting insulin measures circulating insulin after an overnight fast, reflecting pancreatic beta-cell output required to maintain euglycemia. Insulin resistance—the diminished cellular response to insulin—forces the pancreas to secrete more insulin to achieve the same glucose control. Thus, elevated fasting insulin precedes elevated glucose by years to decades.

The Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) integrates fasting glucose and insulin into a single metric: HOMA-IR = (fasting insulin in μU/mL × fasting glucose in mg/dL) ÷ 405. HOMA-IR above 2.0 indicates insulin resistance, though longevity-optimized targets aim for HOMA-IR below 1.0.

A 2025 systematic review published in Frontiers in Endocrinology found that more than 10% of the global adult population exhibits some degree of insulin resistance. A recent analysis of NHANES data revealed that 40% of US adults aged 18-44 are insulin-resistant based on HOMA-IR measurements.

2025 research published in Applied Sciences developed a metabolic syndrome prediction model using HOMA-IR, gender, age, and diabetes status, finding that for every additional year of age, the odds of metabolic syndrome rise by approximately 3.3%. This underscores the substantial impact of insulin resistance and aging on metabolic health.

Insulin resistance is highly modifiable. Resistance training improves insulin sensitivity by increasing muscle glucose uptake capacity, while intermittent fasting and ketogenic diets reduce fasting insulin by 30-50% in clinical trials. Metformin activates AMPK and reduces hepatic glucose output, lowering both fasting insulin and HOMA-IR.

Triglycerides

Triglycerides reflect hepatic very-low-density lipoprotein (VLDL) secretion and peripheral lipoprotein lipase activity. Elevated triglycerides indicate metabolic dysfunction, particularly when combined with low HDL—a pattern termed "atherogenic dyslipidemia." Optimal triglyceride levels remain below 100 mg/dL, though standard reference ranges extend to 150 mg/dL.

The triglyceride-to-HDL ratio (TG:HDL) serves as a proxy for insulin resistance and small-dense LDL particle burden. TG:HDL ratios above 3.0 (using mg/dL units) predict cardiovascular events and diabetes risk independent of LDL cholesterol. Longevity-optimized targets aim for TG:HDL below 1.0.

Triglycerides respond dramatically to carbohydrate restriction, with low-carb diets reducing triglycerides by 30-50% in meta-analyses. Omega-3 fatty acids (EPA and DHA) lower triglycerides through reduced hepatic VLDL synthesis, with prescription omega-3 formulations approved for severe hypertriglyceridemia.

Lipid Panel: Beyond LDL Cholesterol

The standard lipid panel—total cholesterol, LDL-C, HDL-C, and triglycerides—has dominated cardiovascular risk assessment for decades. However, advanced lipid testing and refined metrics offer superior predictive power, particularly for aging populations with discordant traditional markers.

Apolipoprotein B (ApoB): The Superior Metric

ApoB measures the number of atherogenic lipoprotein particles (VLDL, IDL, LDL, and Lp(a)), providing a direct count rather than an estimated cholesterol content. Each atherogenic particle contains exactly one ApoB molecule, making ApoB a precise marker of particle number. In contrast, LDL-C measures cholesterol mass, which varies based on particle size and lipid content.

Multiple large cohort studies demonstrate that ApoB predicts cardiovascular events more accurately than LDL-C, particularly in individuals with metabolic syndrome or diabetes where small-dense LDL particles predominate. Research published in Scientific Reports examined the association of apolipoproteins with later-life all-cause and cardiovascular mortality, finding that ApoB levels robustly predict outcomes stratified by age.

A 2021 Mendelian randomization analysis published in The Lancet Healthy Longevity found that higher ApoB shortens lifespan, increases risks of heart disease and stroke, and in multivariable analyses accounting for LDL cholesterol, increases risk of diabetes. Specifically, a 1-SD higher ApoB led to a 62% lower relative odds of surviving to the 90th centile of longevity.

Current longevity medicine guidelines recommend ApoB below 90 mg/dL for cardiovascular health, with some experts advocating for levels below 80 mg/dL for optimal healthspan. ApoB testing is increasingly recognized as the most important blood marker for long-term heart health, surpassing LDL-C in clinical utility.

ApoB responds to the same interventions as LDL-C—statins, PCSK9 inhibitors, and ezetimibe—but also tracks more closely with dietary changes, particularly saturated fat and carbohydrate reduction. Monitoring ApoB ensures that particle number, not just cholesterol content, is optimized.

Lipoprotein(a) [Lp(a)]

Lp(a) is a genetically determined lipoprotein particle composed of an LDL-like core with an additional apolipoprotein(a) molecule attached. Lp(a) levels are 70-90% heritable and remain stable throughout life, making them a fixed cardiovascular risk factor for most individuals. Elevated Lp(a) (above 30 mg/dL or 75 nmol/L) affects approximately 20% of the population and increases atherosclerotic cardiovascular disease risk independent of LDL-C.

Unlike LDL particles, which respond to statins and diet, Lp(a) is largely refractory to lifestyle interventions. High-dose niacin modestly reduces Lp(a) by 20-30%, though niacin's cardiovascular benefits remain controversial. Emerging therapies including antisense oligonucleotides (pelacarsen) and small interfering RNAs (olpasiran) show promise for reducing Lp(a) by 70-90%, with cardiovascular outcomes trials ongoing.

Individuals with elevated Lp(a) should target aggressive LDL-C and ApoB reduction to offset the additional atherogenic burden. Lp(a) testing is recommended at least once in adulthood, particularly for those with premature cardiovascular disease or family history.

Oxidized LDL (oxLDL)

Oxidized LDL represents LDL particles that have undergone lipid peroxidation, rendering them immunogenic and highly atherogenic. OxLDL is taken up by macrophages via scavenger receptors, driving foam cell formation and plaque development. OxLDL levels predict cardiovascular events independent of LDL-C and are elevated in metabolic syndrome, diabetes, and smoking.

OxLDL is modifiable through antioxidant status and inflammation control. Vitamin E, polyphenols, and NAD+ precursors reduce lipid peroxidation markers in clinical trials. Lowering LDL particle number via statins or PCSK9 inhibitors also reduces oxLDL substrate, making ApoB reduction doubly beneficial.

HDL Cholesterol and Particle Number

HDL cholesterol (HDL-C) has long been viewed as "good cholesterol" due to inverse associations with cardiovascular events. However, Mendelian randomization studies and clinical trials of HDL-raising drugs have failed to demonstrate causality, suggesting HDL-C is a marker of metabolic health rather than a direct protective agent.

Advanced HDL testing measures HDL particle number (HDL-P) and subclass distribution. Small, dense HDL particles are dysfunctional and pro-inflammatory, whereas large, cholesterol-rich HDL particles are atheroprotective. HDL-P below 20th percentile predicts cardiovascular events independent of HDL-C, particularly in individuals with metabolic syndrome.

HDL function—measured by cholesterol efflux capacity—is emerging as a superior metric to HDL-C. Exercise, particularly vigorous aerobic training, improves HDL function and increases large HDL particles. Alcohol consumption modestly raises HDL-C but does not improve function and carries significant health risks.

Kidney Function: Cystatin C Outperforms Creatinine

Kidney function declines with age due to nephron loss, glomerular sclerosis, and vascular changes. Traditional kidney biomarkers—serum creatinine and estimated glomerular filtration rate (eGFR)—have significant limitations, particularly in elderly populations with reduced muscle mass. Cystatin C, a low-molecular-weight protein produced by all nucleated cells, has emerged as a superior alternative.

The Problem with Creatinine

Serum creatinine is a byproduct of muscle metabolism, making it heavily influenced by muscle mass, diet (meat intake), age, and sex. Elderly individuals with sarcopenia produce less creatinine, falsely suggesting preserved kidney function despite declining GFR. Creatinine-based eGFR equations (CKD-EPI, MDRD) attempt to correct for these factors but remain imprecise in non-standard populations.

Cystatin C: The Superior Marker

Cystatin C is produced at a constant rate by all cells, freely filtered by the glomerulus, and reabsorbed but not secreted by renal tubules. Unlike creatinine, cystatin C is independent of muscle mass, making it particularly valuable in elderly, sarcopenic, or highly muscular individuals. Cystatin C-based eGFR (eGFRcys) correlates more closely with measured GFR than creatinine-based eGFR (eGFRcr).

A 2025 cohort study published in Renal Failure examined the association of cystatin C with 20-year mortality risk in the general US population, finding that elevated serum cystatin C levels were associated with increased all-cause mortality across most subgroups. Specifically, cystatin C levels of 0.718-0.932 mg/L and greater than 0.932 mg/L were linked to higher mortality risks, particularly among individuals aged over 59 years, with hazard ratios of 1.545 and 3.458 respectively.

A January 2026 study published in JAMA found that an eGFRcys value that is 30% or more lower than eGFRcr was associated with increased mortality, more cardiovascular events, and a higher risk of kidney failure requiring replacement therapy. This discordance identifies individuals with "true" kidney dysfunction masked by low creatinine production.

2025 research published in the HUNT study demonstrated that using the difference between eGFRcys and eGFRcr significantly improved mortality risk prediction in elderly patients with CKD, though it did not improve kidney failure prediction.

Optimal cystatin C levels remain below 0.9 mg/L, with levels above 1.0 mg/L indicating early kidney dysfunction. Monitoring both creatinine and cystatin C provides a more complete picture of renal health, particularly in aging populations where muscle mass changes confound creatinine-based estimates.

Blood Urea Nitrogen (BUN)

BUN measures urea nitrogen, a waste product of protein metabolism excreted by the kidneys. Elevated BUN suggests reduced kidney function, though it is also influenced by dietary protein intake, hydration status, and catabolic states. The BUN-to-creatinine ratio helps distinguish prerenal azotemia (dehydration, heart failure) from intrinsic kidney disease.

Optimal BUN levels remain between 10-20 mg/dL. Elevated BUN with normal creatinine suggests dehydration or high protein intake, whereas elevated BUN and creatinine together indicate true kidney dysfunction. BUN is less predictive of mortality than cystatin C but remains a useful adjunct marker.

Liver Function: Albumin Decline as an Aging Marker

The liver performs over 500 essential functions, including protein synthesis, detoxification, and metabolic regulation. Liver function tests (LFTs) capture different aspects of hepatic health, with albumin emerging as a particularly important aging biomarker.

Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST)

ALT and AST are intracellular enzymes released when hepatocytes are damaged. ALT is more liver-specific, whereas AST is also present in cardiac and skeletal muscle. Elevated ALT suggests hepatocellular injury from fatty liver disease, alcohol, medications, or viral hepatitis. The AST-to-ALT ratio helps distinguish alcoholic liver disease (AST/ALT greater than 2) from non-alcoholic fatty liver disease (AST/ALT less than 1).

Longevity-optimized targets aim for ALT below 25 U/L in men and below 20 U/L in women, well below standard reference ranges (often 40-50 U/L). Elevated ALT within the "normal" range predicts future metabolic syndrome and cardiovascular events. ALT responds to weight loss, alcohol reduction, and resolution of fatty liver disease through dietary interventions.

Gamma-Glutamyl Transferase (GGT)

GGT is a membrane-bound enzyme involved in glutathione metabolism, found in liver, kidney, and pancreatic cells. Elevated GGT indicates biliary obstruction, alcohol consumption, or oxidative stress. GGT independently predicts cardiovascular events and all-cause mortality, even after adjusting for traditional risk factors.

Optimal GGT levels remain below 30 U/L, with levels above 50 U/L indicating significant oxidative stress or liver dysfunction. GGT is highly responsive to alcohol cessation, with levels normalizing within weeks of abstinence. Antioxidant supplementation (NAD+ precursors, vitamin C, selenium) reduces GGT in clinical trials.

Albumin: The Declining Sentinel

Albumin is the most abundant plasma protein, synthesized exclusively by the liver. It maintains oncotic pressure, transports hormones and fatty acids, and serves as an antioxidant reservoir. Serum albumin levels decline with age, driven by reduced hepatic synthesis, chronic inflammation, and nutritional deficiency.

Research on community-dwelling elderly populations found that serum albumin levels decrease with age in both men and women. Cross-sectional studies show median values decline from 4.3 g/dL in males aged 65-69 years to 3.9 g/dL in those 90 years or older, and from 4.3 g/dL to 4.0 g/dL in females. Longitudinal analysis showed a significant decline of 0.015 g/dL per year in males and 0.012 g/dL per year in females.

Population studies demonstrate that serum albumin concentrations below 3.8 g/dL are associated with increased morbidity, mortality, and disability in the elderly. For every standard deviation decrease in albumin, the relative odds of dying was 1.24, after adjusting for age, sex, and lifestyle factors such as smoking, exercise, and alcohol consumption.

A 2024 systematic review published in PMC confirmed that hypoalbuminemia is a mortality prognostic factor in elderly people, whether they live in the community or are in hospital or institutionalized settings. Chronic low-grade inflammation, commonly observed in aging, leads to decreased albumin synthesis and increased albumin catabolism.

Longevity-optimized targets aim for albumin above 4.5 g/dL, with levels above 4.8 g/dL considered excellent. Maintaining albumin requires adequate protein intake (1.2-1.6 g/kg body weight for older adults), anti-inflammatory interventions, and preservation of liver function. Albumin is a powerful integrative marker of biological age, reflecting nutritional status, inflammation, and hepatic reserve.

Hormone Panels: Endocrine Aging

Hormones regulate metabolism, growth, reproduction, and stress responses. Endocrine function declines with age, contributing to muscle loss, metabolic dysfunction, cognitive decline, and reduced vitality. Hormone panels capture these changes and guide potential interventions.

Insulin-Like Growth Factor 1 (IGF-1)

IGF-1 is produced primarily by the liver in response to growth hormone (GH) and mediates many of GH's anabolic effects. IGF-1 declines with age, contributing to sarcopenia and reduced bone density. However, the relationship between IGF-1 and longevity is complex and context-dependent.

In model organisms, reduced IGF-1/insulin signaling extends lifespan through activation of stress resistance pathways, including FOXO transcription factors and autophagy. Conversely, in humans, very low IGF-1 is associated with frailty, cognitive decline, and mortality, suggesting a U-shaped relationship.

Longevity-optimized IGF-1 levels remain context-dependent. For younger individuals focused on muscle preservation and anabolism, IGF-1 in the mid-normal range (150-250 ng/mL) may be ideal. For older adults or those prioritizing cancer risk reduction, lower IGF-1 (100-150 ng/mL) may be preferable. Protein restriction lowers IGF-1, as does metformin through reduced GH secretion.

Dehydroepiandrosterone Sulfate (DHEA-S)

DHEA-S is the sulfated form of DHEA, an adrenal androgen that serves as a precursor to testosterone and estrogen. DHEA-S peaks in the third decade of life and declines progressively, falling to 10-20% of peak levels by age 70-80. This decline is termed "adrenopause."

Observational studies link low DHEA-S to cardiovascular disease, cognitive decline, and mortality. However, randomized controlled trials of DHEA supplementation in elderly adults show inconsistent benefits, with modest improvements in bone density and mood but no clear effects on muscle mass or mortality.

Optimal DHEA-S levels remain age-dependent, with targets typically set to the mid-normal range for a given age group. DHEA-S responds poorly to lifestyle interventions but can be raised through supplementation (25-50 mg daily for women, 50-100 mg for men), though long-term safety data remain limited.

Testosterone

Testosterone declines in men at approximately 1% per year after age 30, driven by reduced Leydig cell function, increased sex hormone-binding globulin (SHBG), and hypothalamic-pituitary-gonadal axis dysregulation. Low testosterone is associated with sarcopenia, osteoporosis, metabolic syndrome, and reduced vitality.

Total testosterone includes both bound (to SHBG and albumin) and free testosterone. Free testosterone represents the bioavailable fraction and correlates more closely with symptoms than total testosterone. Longevity-optimized targets for total testosterone are above 500 ng/dL, with free testosterone above 10 ng/dL.

Testosterone responds to resistance training, weight loss, and improved sleep. Testosterone replacement therapy (TRT) increases muscle mass, bone density, and quality of life in hypogonadal men, though cardiovascular safety remains under investigation. Monitoring hematocrit and prostate-specific antigen (PSA) is essential during TRT.

Thyroid Function: TSH, Free T3, and Free T4

Thyroid hormones regulate metabolism, thermogenesis, and cellular energy production. Thyroid-stimulating hormone (TSH) is secreted by the pituitary to stimulate thyroid hormone production. Elevated TSH with low free T4 indicates hypothyroidism, whereas low TSH with elevated free T3/T4 suggests hyperthyroidism.

Subclinical hypothyroidism—elevated TSH with normal free T4—affects 10-15% of adults over 65 and is associated with dyslipidemia, cognitive decline, and cardiovascular risk. Optimal TSH levels remain between 1.0-2.5 mIU/L, well below the upper limit of standard reference ranges (often 4.0-5.0 mIU/L).

Free T3 represents the active thyroid hormone and declines with age due to reduced peripheral conversion of T4 to T3. Low free T3 with normal TSH and free T4 suggests "low T3 syndrome," common in chronic illness and caloric restriction. Maintaining free T3 in the mid-normal range supports metabolic health, though excessive thyroid hormone replacement accelerates bone loss and atrial fibrillation.

Cortisol

Cortisol is the primary glucocorticoid hormone, secreted by the adrenal glands in response to stress. Cortisol follows a diurnal rhythm, peaking in the morning and declining throughout the day. Chronic stress and aging disrupt this rhythm, leading to flattened cortisol curves and elevated evening cortisol.

Elevated cortisol drives muscle catabolism, insulin resistance, and visceral fat accumulation. Morning cortisol below 10 μg/dL suggests adrenal insufficiency, whereas levels above 20 μg/dL indicate chronic stress or Cushing's syndrome. Optimal cortisol rhythms maintain morning peaks (10-15 μg/dL) with undetectable evening levels (less than 2 μg/dL).

Cortisol responds to stress management, sleep optimization, and adaptogenic herbs (ashwagandha, rhodiola). Exercise acutely raises cortisol but improves cortisol regulation long-term through enhanced hypothalamic-pituitary-adrenal axis sensitivity.

Complete Blood Count: The Lymphocyte-Monocyte Ratio and RDW

The complete blood count (CBC) is one of the most routine blood tests, measuring red blood cells, white blood cells, and platelets. Beyond detecting anemia and infection, specific CBC components have emerged as aging biomarkers.

Lymphocyte-to-Monocyte Ratio (LMR)

The lymphocyte-to-monocyte ratio reflects immune system balance, with declining lymphocytes and rising monocytes characterizing immunosenescence. Research published in Frontiers in Bioscience identifies LMR as one of the senescence-independent changes characterizing immunosenescence, alongside alterations in naive:memory T cell ratio, CD4:CD8 ratio, and thymic atrophy.

A 2025 study in Frontiers in Immunology found that aging is associated with higher monocyte counts, lower lymphocyte counts, and a higher monocyte-to-lymphocyte ratio. 2026 research published in Immunology describes how aging drives immunosenescence through T-cell dysfunction, thymic involution, B cell aging, an imbalance in the ratio of naïve to memory cells, chronic inflammation (inflammaging), and metabolic dysregulation.

Optimal LMR remains above 3.0, with ratios below 2.0 suggesting immune dysregulation. LMR responds to exercise, which enhances lymphocyte trafficking and function, and to anti-inflammatory interventions that reduce monocyte activation.

Red Cell Distribution Width (RDW): A Powerful Mortality Predictor

RDW measures the variability in red blood cell size, traditionally used to differentiate types of anemia. However, RDW has emerged as a robust predictor of all-cause mortality, cardiovascular events, and frailty, independent of hemoglobin levels.

A 2025 study published in BMC Musculoskeletal Disorders found that red blood cell distribution width is a short-term mortality predictor in middle-aged and older adults with hip fracture. 2025 research in Frontiers in Aging Neuroscience examined RDW in critically ill patients with delirium, finding elevated RDW is a recognized marker of sustained systemic inflammation characterized by elevated pro-inflammatory cytokines.

A 2026 study published in PLOS ONE found that age and RDW are independent predictors of short-term mortality in traumatic brain injury, with RDW partially mediating the effect of age on outcome. Meta-analysis shows that for every 1% increment in RDW, total mortality risk in older adults increased by 14%.

The mechanism linking RDW to mortality involves chronic inflammation, oxidative stress, nutritional deficiencies (iron, folate, B12), and ineffective erythropoiesis. Elevated RDW reflects systemic dysregulation rather than a single pathological process, making it a powerful integrative biomarker.

Optimal RDW remains below 13.5%, with levels above 14.5% predicting increased mortality risk. RDW responds to iron repletion, vitamin B12 and folate supplementation, and anti-inflammatory interventions. Monitoring RDW longitudinally provides early warning of declining health status.

Composite Aging Panels: PhenoAge and Beyond

Individual biomarkers provide valuable insights, but composite algorithms integrating multiple markers offer superior predictive power. PhenoAge, developed by Dr. Morgan Levine and colleagues at Yale, represents the most validated blood-based biological age calculator.

PhenoAge: Nine Biomarkers Predicting Mortality

PhenoAge was developed in 2018 using data from the National Health and Nutrition Examination Survey (NHANES) to identify biomarkers that best predict mortality risk. The algorithm uses chronological age and nine blood biomarkers: albumin, creatinine, glucose, C-reactive protein (CRP), lymphocyte percent, mean cell volume (MCV), red blood cell distribution width (RDW), alkaline phosphatase (ALP), and white blood cell count (WBC).

The hypothesis was that incorporation of composite clinical measures of phenotypic age that capture differences in lifespan and healthspan may identify novel markers and facilitate the development of a more powerful epigenetic biomarker of aging. The resulting DNAm PhenoAge strongly outperforms previous measures in predictions for all-cause mortality, cancers, healthspan, and physical functioning.

Each one-year increase in PhenoAge above chronological age is associated with a 9% increase in mortality risk. 2023 research published in Internal and Emergency Medicine confirmed that biological age is superior to chronological age in predicting hospital mortality of the critically ill.

The Levine PhenoAge was validated to be predictive of 10-year survival, cognitive dysfunction, and diabetes mellitus over and beyond a person's chronological age. The beauty of PhenoAge is that it requires only standard lab tests available at any clinical laboratory, making it accessible for longitudinal tracking.

PhenoAge calculation is available through online calculators and commercial testing services. Monitoring PhenoAge over time allows individuals to assess whether interventions are slowing biological aging. Successful aging interventions should produce PhenoAge values below chronological age.

The Aging.AI Algorithm: Deep Learning on Blood Panels

Aging.AI represents the next generation of biological age estimation, using deep learning to analyze standard blood tests. Deep learning and generative artificial intelligence are being used in biomarker discovery, deep aging clock development, geroprotector identification, and generation of dual-purpose therapeutics targeting aging and disease.

Standard blood test results can be uploaded to AI systems to receive AI-calculated biological age instantly. These algorithms work with common panels like CBC, metabolic panel, and lipid panel, with some algorithms incorporating 12 validated aging biomarkers that collectively provide a comprehensive picture of physiological age.

A new AI-based method called gtAge integrates IgG N-glycome and blood transcriptome data using deep reinforcement learning to estimate biological age with 85% accuracy, surpassing single-data approaches. Recent models include transformer-based approaches that incorporate morbidity and mortality information to improve predictive accuracy and enhance clinical utility in early identification of risk for age-related diseases.

In 2018, Mamoshina et al. constructed a hematological deep aging clock trained on standard laboratory tests from 3 different populations, showing the difference between their aging rates. The field continues to evolve rapidly with increasingly sophisticated deep learning architectures improving the accuracy of biological age estimation from blood biomarkers.

An explainable machine learning framework for biomarker discovery combines biological age and frailty prediction, published in 2025 in Scientific Reports. These AI-driven approaches not only calculate biological age but also identify which specific biomarkers are driving accelerated aging in individual patients, enabling targeted interventions.

Interventions and Biomarker Changes: What Actually Works

Understanding biomarkers is only valuable if they respond to interventions. This section summarizes evidence-based approaches for modifying key aging biomarkers.

Exercise: The Universal Biomarker Improver

Exercise is the most potent non-pharmacological intervention for improving blood biomarkers. Aerobic exercise reduces hsCRP by 20-40%, lowers triglycerides, improves insulin sensitivity, and increases HDL function. Resistance training increases muscle mass, raising testosterone and lowering HOMA-IR. High-intensity interval training (HIIT) combines both benefits with superior time efficiency.

Exercise also reduces GDF-15 in individuals with mitochondrial dysfunction, improves mitochondrial function, and enhances lymphocyte function, improving LMR. The dose-response is clear: more exercise produces greater biomarker improvements, with diminishing returns above 60-90 minutes of moderate-to-vigorous activity per day.

Caloric Restriction and Fasting

Caloric restriction (15-40% reduction in caloric intake without malnutrition) is the most robust lifespan extension intervention in model organisms. In humans, caloric restriction lowers fasting glucose, HbA1c, insulin, HOMA-IR, triglycerides, CRP, and IGF-1. The CALERIE trial demonstrated that 2 years of 25% caloric restriction in non-obese adults reduced all major cardiometabolic risk factors and lowered biological age assessed by multiple clocks.

Time-restricted eating (TRE), typically an 8-10 hour daily eating window, produces similar metabolic benefits without requiring calorie counting. TRE lowers fasting insulin by 20-30%, reduces triglycerides, and improves circadian alignment of metabolic processes. Periodic prolonged fasting (2-5 days every 1-3 months) enhances autophagy, reduces IGF-1, and promotes immune system rejuvenation through hematopoietic stem cell activation.

Metformin: The Best-Studied Geroprotector

Metformin, a first-line diabetes medication, activates AMPK and inhibits mitochondrial complex I, mimicking aspects of caloric restriction. Metformin lowers fasting glucose, HbA1c, insulin, HOMA-IR, and CRP. Observational studies show metformin users have lower all-cause mortality compared to non-diabetic controls, suggesting direct anti-aging effects beyond glucose control.

The TAME (Targeting Aging with Metformin) trial is investigating whether metformin delays aging-related diseases in non-diabetic older adults. Typical doses are 500-1000 mg twice daily, with gastrointestinal side effects managed through gradual dose escalation and extended-release formulations. Metformin may reduce vitamin B12 absorption, necessitating periodic monitoring and supplementation.

NAD+ Precursors: Targeting Mitochondrial Function

NAD+ (nicotinamide adenine dinucleotide) declines with age, impairing mitochondrial function, DNA repair, and sirtuin activity. NAD+ precursors—nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN)—raise NAD+ levels in human trials, though clinical outcome data remain limited.

Small trials show NR/NMN supplementation (500-1000 mg daily) improves insulin sensitivity, lowers blood pressure, and reduces inflammatory markers in some but not all studies. The impact on GDF-15 is of particular interest given GDF-15's role as a mitochondrial stress biomarker. Long-term randomized controlled trials are needed to determine whether NAD+ precursors meaningfully alter aging trajectories.

Sleep Optimization

Poor sleep quality and duration increase cortisol, CRP, IL-6, glucose, and insulin resistance. Sleep deprivation reduces testosterone, GH secretion, and immune function. Conversely, optimizing sleep (7-9 hours of high-quality sleep with intact slow-wave and REM phases) normalizes these biomarkers.

Sleep interventions include cognitive behavioral therapy for insomnia (CBT-I), chronotherapy (light exposure optimization), temperature regulation, and targeted supplementation (magnesium, glycine, melatonin). Monitoring sleep with wearable devices (Oura Ring, WHOOP) allows personalized optimization based on objective metrics.

Optimal Ranges vs Reference Ranges: The Longevity Gap

Standard laboratory reference ranges are derived from the middle 95% of the tested population, typically diseased individuals seeking medical care. These ranges identify pathology but do not define optimal health. Longevity-optimized ranges target values associated with extended healthspan and reduced mortality in epidemiological studies.

Biomarker Standard Reference Range Longevity-Optimized Target
hsCRP <3.0 mg/L <0.5 mg/L
Fasting Glucose 70-100 mg/dL 70-85 mg/dL
HbA1c <5.7% <5.4%
HOMA-IR <2.0 <1.0
Triglycerides <150 mg/dL <100 mg/dL
ApoB <130 mg/dL <80 mg/dL
Cystatin C 0.6-1.2 mg/L <0.9 mg/L
ALT <40 U/L <25 U/L (men), <20 U/L (women)
Albumin 3.5-5.5 g/dL >4.5 g/dL
TSH 0.5-5.0 mIU/L 1.0-2.5 mIU/L
Testosterone (men) 300-1000 ng/dL >500 ng/dL
RDW 11.5-15.0% <13.5%
GDF-15 No standard range <400 pg/mL (middle-aged)

Achieving longevity-optimized ranges requires proactive intervention, not merely absence of disease. This distinction separates disease management from aging optimization—the frontier of personalized medicine.

Testing Frequency and Longitudinal Tracking

Single biomarker measurements provide snapshots, but aging is a dynamic process. Longitudinal tracking—repeated measurements over months to years—captures individual trajectories and intervention responses. Establishing personal baselines is essential because inter-individual variability in biomarkers often exceeds intra-individual variability.

Baseline Establishment (First 6-12 Months)

Begin with comprehensive panels every 3 months to establish baseline patterns and identify outliers requiring intervention. Include standard panels (CBC, CMP, lipid panel) plus specialized markers (hsCRP, HOMA-IR, cystatin C, GDF-15). Calculate PhenoAge at each time point.

Intervention Testing (Months 6-24)

When implementing interventions (dietary changes, exercise programs, supplements, medications), increase testing frequency to every 2-3 months to capture responses. This period identifies which interventions move the needle and establishes dose-response relationships.

Maintenance Monitoring (Years 2+)

Once biomarkers are optimized and stable, reduce testing to every 6-12 months for maintenance monitoring. More frequent testing is warranted after age 50 or when implementing new interventions. Annual comprehensive panels including advanced lipids (ApoB, Lp(a)), hormone panels, and emerging biomarkers (GDF-15, cystatin C) provide early detection of age-related decline.

Data Visualization and Analysis

Track biomarkers using spreadsheets or dedicated longevity tracking platforms. Visualize trends with line graphs, flagging values outside longevity-optimized ranges. Calculate year-over-year changes to quantify aging rate. Integrate biomarker data with wearable biometrics (sleep, HRV, activity) and functional assessments (grip strength, VO2max) for comprehensive phenotyping.

Integration with Multi-Omic Aging Assessment

Blood biomarkers represent one layer of aging assessment. Multi-omic profiling—genomics, transcriptomics, proteomics, metabolomics, and microbiomics—provides deeper mechanistic insights but remains expensive and inaccessible for routine use. Blood biomarkers serve as the foundation, with multi-omics reserved for investigational contexts or when standard biomarkers yield ambiguous results.

Epigenetic clocks measure DNA methylation patterns, offering a complementary biological age estimate. The strongest aging assessments integrate blood biomarkers (PhenoAge), epigenetic clocks (GrimAge, DunedinPACE), and functional measures (grip strength, gait speed, VO2max). This triangulation separates signal from noise and identifies discordant aging across physiological systems.

Conclusion: From Data to Action

Blood biomarkers transform aging from an abstract, inevitable process into a measurable, modifiable phenomenon. The biomarkers discussed—from canonical markers like glucose and lipids to emerging stars like GDF-15 and cystatin C—provide actionable targets for intervention. Composite algorithms like PhenoAge and deep learning models like Aging.AI distill dozens of markers into single, interpretable biological age scores.

The key is action. Measuring biomarkers without intervention is academic curiosity; measuring biomarkers to guide optimization is precision medicine. The evidence base supporting exercise, caloric restriction, sleep optimization, and targeted geroprotectors like metformin is robust and growing. The tools are available. The question is implementation.

Longitudinal tracking establishes personal baselines, quantifies intervention responses, and detects early deviations from optimal trajectories. This data-driven approach—measure, intervene, re-measure—accelerates progress toward extended healthspan. Blood biomarkers are not merely diagnostic tools; they are feedback signals in the active management of biological age.

The future of aging science lies in integrating blood biomarkers with continuous wearable monitoring, multi-omic profiling, and AI-driven personalization. But the present opportunity is already transformative: routine blood tests, interpreted through a longevity lens, offer immediate, actionable insights. The window into aging is open. The question is whether we choose to look—and act on what we see.

Cross-References and Further Reading

Sources